Ascendis Pharma A/S (ASND) Stock Formed Bullish Double Top Chart Pattern. What To Expect?

April 20, 2018 - By Adrian Erickson

The chart of Ascendis Pharma A/S (ASND) shows a double top with $67.98 target or 6.00 % above today’s $64.13 share price. The 7 months chart pattern indicates low risk for the $2.66B company. It was reported on Apr, 20 by Finviz.com. If the $67.98 price target is reached, the company will be worth $159.78 million more. Double tops are rare but powerful chart patterns.

The stock decreased 1.35% or $0.88 during the last trading session, reaching $64.13. About 59,763 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 130.09% since April 20, 2017 and is uptrending. It has outperformed by 118.54% the S&P500.

Analysts await Ascendis Pharma A/S (NASDAQ:ASND) to report earnings on May, 22. They expect $-0.89 earnings per share, down 7.23 % or $0.06 from last year’s $-0.83 per share. After $-1.08 actual earnings per share reported by Ascendis Pharma A/S for the previous quarter, Wall Street now forecasts -17.59 % EPS growth.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 4 analysts covering Ascendis Pharma A\/S (NASDAQ:ASND), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ascendis Pharma A\/S has $78 highest and $43 lowest target. $68.50’s average target is 6.81% above currents $64.13 stock price. Ascendis Pharma A\/S had 11 analyst reports since November 17, 2017 according to SRatingsIntel. As per Monday, February 26, the company rating was maintained by Wedbush. As per Tuesday, March 20, the company rating was maintained by Credit Suisse. The rating was maintained by Wedbush on Wednesday, April 4 with “Buy”. Bank of America maintained Ascendis Pharma A/S (NASDAQ:ASND) on Thursday, January 25 with “Buy” rating. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Friday, January 5. Wedbush has “Buy” rating and $62.0 target. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) on Tuesday, February 6 with “Buy” rating. Bank of America maintained it with “Buy” rating and $43 target in Friday, November 17 report. Wedbush maintained the shares of ASND in report on Monday, March 19 with “Buy” rating. As per Thursday, February 22, the company rating was maintained by Credit Suisse. As per Wednesday, January 17, the company rating was maintained by J.P. Morgan.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: